August 19, 2021 News by Marta Figueiredo, PhD MediciNova Planning Phase 3 Trial of Oral Ibudilast for SPMS MediciNovaĀ is planning to launch a Phase 3 clinical trial that will evaluate its investigational oral candidate ibudilast (MN-166) in people with secondary progressive multiple sclerosis (SPMS) without relapses. The company is actively engaging with potential partners that could help fund the study. āOver the past quarter, we…
July 8, 2021 News by Patricia Inacio, PhD Ibudilast, Potential Progressive MS Therapy, Awaits US Patent MediciNovaĀ announced that it will be given a U.S. patent covering the use of ibudilastĀ (MN-166) in treating eye disease. This oral medication aims to lessen inflammation, including that of progressiveĀ multiple sclerosis (MS). Specifically, it will cover ibudilast’s use in Ā treating injury or damage to the macula ā…
January 26, 2021 News by Aisha I Abdullah PhD PPMS Patients ‘Drove’ Slowing in Brain Atrophy Seen With Ibudilast, Trial Analysis Finds People with primary progressive MS (PPMS) appeared to show a much stronger response and to be the” driving” force behind a slowing in brain atrophy seen withĀ ibudilastĀ treatment in the SPRINTāMS trial, a post-hoc study analysis reports. The treatment response observed in brain atrophy was more evident…
November 12, 2020 News by Forest Ray PhD Non-invasive Imaging Technique Reveals Ibudilast’s Neuroprotective Effect A non-invasive retina imaging technique known as optical coherence tomography (OCT) provided evidence of the neuroprotective effect of ibudilastĀ (MN-166) ā an oral medication designed to reduce the body’s inflammatory responses āĀ in people with progressive forms of multiple sclerosis (MS). The data also…
November 22, 2019 News by Ana Pena PhD Ocrevus Top Choice of US Neurologists for Active SPMS, But Mayzent and Mavenclad Gaining Interest, Report Says Genentech‘sĀ OcrevusĀ (ocrelizumab) continues to be the most prescribed medication to reduce inflammatory disease in people with active secondary progressive multiple sclerosisĀ (SPMS) amongĀ U.S. neurologists, even though Novartis’Ā MayzentĀ (siponimod) and EMD Serono’sĀ MavencladĀ (cladribine) were approved in March to treat this same MS…
July 17, 2019 News by Ana Pena PhD Phase 3 Trial of Ibudilast Planned for SPMS Patients with Inactive Disease, MediciNova Says A Phase 3 trial is planned to confirm the safety and efficacy of oral ibudilast (MN-166) in treating people with secondary progressive multiple sclerosis (SPMS) without relapses, or those whose disease is not active, MediciNovaĀ announced. Data from this single Phase 3 study may be used to request…
April 4, 2019 News by Jose Marques Lopes, PhD #AANAM – Ibudilast Slows Brain Atrophy in PPMS But Not SPMS Patients, Phase 2b Trial Shows Treatment with oral ibudilast slowsĀ brain shrinkage in patients with primary progressive multiple sclerosis (PPMS), but not in those with secondary progressive MS (SPMS), according to results of a Phase 2b clinical trial. According to the findings, this could be partially due to faster disease progression in untreated…
September 18, 2018 News by Jose Marques Lopes, PhD Ibudilast Slows Brain Shrinkage 48% in Progressive MS Patients in Phase 2 Trial; Lead Researcher Says Finding is ‘Remarkable’ Progressive multiple sclerosis patients ā with primary or secondary progressive disease ā treated with high doses of oralĀ ibudilastĀ in a Phase 2 clinical trial showed a 48 percent slowing in the progression of brain atrophy, or shrinkage, relative to those given a placebo, study data show. What this…
February 2, 2018 News by Patricia Inacio, PhD #ACTRIMS2018 ā MediciNova Presents Positive Results from SPRINT-MS Trial Evaluating Ibudilast in Progressive MS Top-line results from a clinical trial evaluating the investigational oral therapy ibudilast for progressive multiple sclerosis (MS) show that the therapy led to a significant reduction of brain atrophy in patients when compared to controls. Robert Naismith, MD, one of the study’s principal researchers fromĀ Washington University in St. Louis,…
October 30, 2017 News by Patricia Inacio, PhD #MSParis2017 – Ibudilast Slows Loss of Brain Tissue in MS Patients, Phase 2 Trial Shows The Japanese companyĀ MediciNova‘s anti-inflammatory agentĀ ibudilast slows multiple sclerosis patients’ brain shrinkage and their loss of the protective myelin coating around nerve cells, a Phase 2 clinical trial shows. Robert J. Fox of Ohio’s Cleveland Clinic Neurological InstituteĀ presented the results at theĀ 7th Joint ECTRIMS-ACTRIMS MeetingĀ in Paris, Oct. 25-28.
September 1, 2017 News by Patricia Silva, PhD #MSParis2017 – MediciNova to Share Results of Ibudilast Trial in Progressive MS at October Summit MediciNova will present data from its clinical trial of ibudilast (MN-166) in progressive multiple sclerosis (MS) at the upcoming 7th Joint ECTRIMS – ACTRIMS Meeting in Paris. The European and American Committees for Treatment and Research in Multiple Sclerosis (ECTRIMS and ACTRIMS) selected the presentation “…
December 22, 2016 News by Patricia Silva, PhD Use of Ibudilast as MS Treatment Shows Enough Promise to Continue Trial Ibudilast (MN-166) has shown enough promise as a treatment for progressive multiple sclerosis (MS) that its U.S.Ā Phase 2b trial (NCT01982942) should continue, the U.S. National Institute of Health’s Data and Safety Monitoring Board has recommended. A key goal of the 96-week trial is to determine whether ibudilast canĀ slow the…
March 23, 2016 News by Patricia Silva, PhD Potential Progressive MS Treatment, Ibudilast, Approved for Fast Track Development by FDA MediciNova, Inc.,Ā announced that MN-166 (ibudilast) has been approved for “fast track” development byĀ the U.S. Food and Drug Administration (FDA)Ā as a potentialĀ treatment forĀ progressive multiple sclerosis (MS).Ā Progressive MS includesĀ both the primary progressive (PPMS) and secondary progressive (SPMS) forms of the disease. MediciNovaās MN-166 was licensed from Kyorin Pharmaceuticals for its potential…
June 15, 2015 News by Patricia Silva, PhD MediciNova Announces Update On Phase 2b Trial of MN-166 (Ibudilast) Involving 255 Progressive MS Patients MediciNova, Inc., a biopharmaceutical company focused on acquiring and developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the ongoing clinical trial of MN-166 (ibudilast) in patients with progressive multiple sclerosis (progressive MS) has finished the randomization of 255 patients, exceeding the…
May 8, 2015 News by Patricia Silva, PhD MediciNova Completes Enrollment for Phase 2b Study of Experimental Progressive Multiple Sclerosis Treatment MediciNova, Inc., a publicly-traded biopharmaceutical company developing novel, small-molecule therapeutics for the treatment of diseases with unmet medical needs, recently announced that the National Institute of Neurological Disorders and Stroke (NINDS) notified the company of full enrollment of theirĀ ongoing clinical study evaluating ibudilastĀ (MN-166) for the treatment of progressive…
February 4, 2015 News by admin MediciNova To Present on Multiple Sclerosis Therapy at American Academy of Neurology 67th Annual Meeting MediciNova, Inc., has announcedĀ the acceptance ofĀ an abstractĀ describing their ongoing Phase 2b clinical trial of MN-166 (ibudilast) in progressive multiple sclerosis (MS). The poster is to be presented at the American Academy of Neurology (AAN) 67th Annual Meeting, April 18 – 25, 2015 in Washington, DC. The presentation is titled…
September 24, 2014 News by Maureen Newman Primary, Secondary Progressive MS Therapy to be Tested in Phase 2 Trial by MediciNova MediciNova, Inc., recently announced that it had surpassed 50% enrollment for the phase 2b clinical trial evaluating MN-166 (ibudilast) in progressive multiple sclerosis patients. As of September 15th, 150 of an expected 250 patients have enrolled for treatment, and the trial is on track to complete enrollment by the…